Not yet recruiting
Breast cancer
Not yet recruitingA study to evaluate if silymarin prevents liver damage caused by ribociclib in patients with hormone receptor positive, HER2-negative breast cancer
Registered drugNo placebo
A study to evaluate if silymarin prevents liver damage caused by ribociclib in patients with hormone receptor positive, HER2-negative breast cancer
Registered drugNo placebo
- Disease:Breast cancer
- Substances:RibociclibSilymarin
Countries:
Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Ribociclib